Citations (17)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Vicente Gimeno-Ballester, Javier Mar, Aisling O’Leary, Róisín Adams & Ramón San Miguel. (2017) Cost-effectiveness analysis of therapeutic options for chronic hepatitis C genotype 3 infected patients. Expert Review of Gastroenterology & Hepatology 11:1, pages 85-93.
Read now
Read now
Vicente Gimeno-Ballester, Javier Mar & Ramón San Miguel. (2016) Cost–effectiveness analysis of simeprevir with daclatasvir for non-cirrhotic genotype-1b-naïve patients plus chronic hepatitis C. Expert Review of Pharmacoeconomics & Outcomes Research 16:2, pages 285-294.
Read now
Read now
Eric Druyts, Kristian Thorlund & Edward J. Mills. (2014) Letter to the Editor. Journal of Medical Economics 17:7, pages 445-445.
Read now
Read now
Ramón San Miguel, Vicente Gimeno-Ballester & Javier Mar. (2014) Cost-effectiveness of protease inhibitor based regimens for chronic hepatitis C: a systematic review of published literature. Expert Review of Pharmacoeconomics & Outcomes Research 14:3, pages 387-402.
Read now
Read now
Articles from other publishers (13)
Rodolfo Castro, Louise Crathorne, Hugo Perazzo, Julio Silva, Chris Cooper, Jo Varley-Campbell, Daniel Savignon Marinho, Marcela Haasova, Valdilea G. Veloso, Rob Anderson & Chris Hyde. (2018) Cost-effectiveness of diagnostic and therapeutic interventions for chronic hepatitis C: a systematic review of model-based analyses. BMC Medical Research Methodology 18:1.
Crossref
Crossref
Andrew J. Leidner, Harrell W. Chesson, Philip R. Spradling & Scott D. Holmberg. (2016) Assessing the Effect of Potential Reductions in Non-Hepatic Mortality on the Estimated Cost-Effectiveness of Hepatitis C Treatment in Early Stages of Liver Disease. Applied Health Economics and Health Policy 15:1, pages 65-74.
Crossref
Crossref
Roberto Nuño Solinís, Patricia Arratibel Ugarte, Ander Rojo & Yuri Sanchez Gonzalez. (2016) Value of Treating All Stages of Chronic Hepatitis C: A Comprehensive Review of Clinical and Economic Evidence. Infectious Diseases and Therapy 5:4, pages 491-508.
Crossref
Crossref
Jona T. Stahmeyer, Siegbert Rossol, Florian Bert, Klaus H. W. Böker, Harald-Robert Bruch, Christoph Eisenbach, Ralph Link, Christine John, Stefan Mauss, Renate Heyne, Eckart Schott, Heike Pfeiffer-Vornkahl, Dietrich Hüppe & Christian Krauth. (2016) Outcomes and Costs of Treating Hepatitis C Patients in the Era of First Generation Protease Inhibitors – Results from the PAN Study. PLOS ONE 11:7, pages e0159976.
Crossref
Crossref
Jagpreet Chhatwal, Tianhua He & Maria A. Lopez-Olivo. (2016) Systematic Review of Modelling Approaches for the Cost Effectiveness of Hepatitis C Treatment with Direct-Acting Antivirals. PharmacoEconomics 34:6, pages 551-567.
Crossref
Crossref
Ramón San Miguel, Vicente Gimeno-Ballester, Antonio Blázquez & Javier Mar. (2015) Cost-effectiveness analysis of sofosbuvir-based regimens for chronic hepatitis C. Gut 64:8, pages 1277-1288.
Crossref
Crossref
Jona T Stahmeyer, Siegbert Rossol & Christian Krauth. (2015) Outcomes, costs and cost–effectiveness of treating hepatitis C with direct acting antivirals. Journal of Comparative Effectiveness Research 4:3, pages 267-277.
Crossref
Crossref
Katelijne van de Vooren, Alessandro Curto & Livio Garattini. (2014) Pricing of forthcoming therapies for hepatitis C in Europe: beyond cost-effectiveness?. The European Journal of Health Economics 16:4, pages 341-345.
Crossref
Crossref
Emma Warren, Alison Wright & Brandon Jones. (2014) Cost-Effectiveness of Telaprevir in Patients with Genotype 1 Hepatitis C in Australia. Value in Health 17:8, pages 792-800.
Crossref
Crossref
Aikaterini Vellopoulou, Michel van Agthoven, Annemarie van der Kolk, Robert J. de Knegt, Gilles Berdeaux, Sandrine Cure, Florence Bianic & Mark Lamotte. (2014) Cost Utility of Telaprevir–PR (Peginterferon–Ribavirin) Versus Boceprevir–PR and Versus PR Alone in Chronic Hepatitis C in The Netherlands. Applied Health Economics and Health Policy 12:6, pages 647-659.
Crossref
Crossref
Dalibor Novotny, Lucie Roubalova, Kvetoslava Aiglova, Jana Bednarikova & Margita Bartkova. (2014) IL28B genotyping and treatment of HCV infected subjects. Asian Biomedicine 8:4, pages 445-452.
Crossref
Crossref
Christoph Höner zu Siederdissen & Markus Cornberg. (2014) Sofosbuvir for the treatment of patients with genotype 2 or 3 chronic hepatitis C virus infection. Clinical Investigation 4:4, pages 361-371.
Crossref
Crossref
Béla Hunyady, Judit Gervain, Gábor Horváth, Mihály Makara, Alajos Pár, Ferenc Szalay, László Telegdy & István Tornai. (2014) Diagnosis, treatment, and follow-up of hepatitis C-virus related liver disease. Hungarian national consensus guideline. Orvosi Hetilap 155:Supplement 2, pages 3-24.
Crossref
Crossref